Forest ends deal for Phenomix's Phase III dutogliptin
Forest Laboratories and Phenomix (lead programs for diabetes and hepatitis C) have partnered to develop and commercialize Phenomix's Phase III dutogliptin (PHX1149) for Type II diabetes in North America.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com